Entrada Therapeutics (TRDA) EBT (2020 - 2026)
Entrada Therapeutics (TRDA) posted quarterly EBT of -$39.7 million for Q1 2026, down 128.71% year-over-year from $138.2 million in Q1 2025, and down 1.55% quarter-over-quarter from -$39.1 million in Q4 2025.
Powered by 
Analysis
Entrada Therapeutics (TRDA) EBT (2020 - 2026) Analysis & Trends
Entrada Therapeutics' EBT history runs 7 years deep, the most recent figure standing at -$39.7 million for Q1 2026.
- In Q1 2026, EBT fell 128.71% year-over-year to -$39.7 million; the TTM figure through Mar 2026 stood at -$165.2 million (down 793.67% YoY), while the FY2025 annual figure was -$142.8 million, down 314.82% from the prior year.
- EBT for Q1 2026 stood at -$39.7 million, down from -$39.1 million in the prior quarter.
- The five-year high for EBT was $57.8 million in Q2 2024, with the low at -$43.5 million in Q3 2025.
- The 5-year median for EBT is -$17.3 million (2025), against an average of -$11.7 million.
- The sharpest annual moves came in 2024 and 2025: EBT soared 910.98% in 2024, then sank 5187.14% in 2025.
- Entrada Therapeutics' EBT stood at -$24.6 million in 2022, then surged by 137.34% to $9.2 million in 2023, then sank by 108.04% to -$739000.0 in 2024, then sank by 5187.14% to -$39.1 million in 2025, then fell by 1.55% to -$39.7 million in 2026.
- Business Quant data shows TRDA's EBT at -$39.7 million in Q1 2026, -$39.1 million in Q4 2025, and -$43.5 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.27 Bn | 131.42 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 85.55 Bn | 77.56 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 63.45 Bn | 58.27 Bn | 1.37 Bn | 542.00 Mn |
| 4 | Moderna | 57.73 Bn | 52.59 Bn | 52.00 Mn | -767.00 Mn |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 312.46 Mn |
| 7 | Alnylam Pharmaceuticals | 35.14 Bn | 31.84 Bn | 992.69 Mn | 177.81 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | -11.37 Mn |
| 10 | Entrada Therapeutics | 301.04 Mn | 301.04 Mn | - | -42.73 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -42.73 Mn |
| Mar 31, 2026 | -39.68 Mn |
| Dec 31, 2025 | -39.07 Mn |
| Sep 30, 2025 | -43.48 Mn |
| Jun 30, 2025 | -42.93 Mn |
| Mar 31, 2025 | -17.35 Mn |
| Dec 31, 2024 | -724,000.00 |
| Sep 30, 2024 | -15.89 Mn |
| Jun 30, 2024 | 57.79 Mn |
| Mar 31, 2024 | 25.33 Mn |
| Dec 31, 2023 | 9.24 Mn |
| Sep 30, 2023 | 18.06 Mn |
| Jun 30, 2023 | -12.08 Mn |
| Mar 31, 2023 | -3.12 Mn |
| Dec 31, 2022 | -24.63 Mn |
| Sep 30, 2022 | -25.14 Mn |
| Jun 30, 2022 | -23.18 Mn |
| Mar 31, 2022 | -21.67 Mn |
| Dec 31, 2021 | -18.45 Mn |
| Sep 30, 2021 | -14.43 Mn |